NFKB1 and diffuse large B-cell lymphoma: Bortezomib, a proteasome inhibitor that downregulates NF-kB by decreasing the degradation of inhibitory kB proteins [190], has shown no benefit in phase II and III trials when combined with R-CHOP in de novo ABC DLBCL [191,192,193].